Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2005 1
2006 2
2007 1
2009 1
2010 2
2011 1
2012 3
2013 2
2014 2
2015 2
2016 4
2017 4
2018 6
2019 1
2020 8
2021 6
2022 4
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
KMT2C and KMT2D aberrations in breast cancer.
Tinsley E, Bredin P, Toomey S, Hennessy BT, Furney SJ. Tinsley E, et al. Among authors: toomey s. Trends Cancer. 2024 Mar 6:S2405-8033(24)00029-3. doi: 10.1016/j.trecan.2024.02.003. Online ahead of print. Trends Cancer. 2024. PMID: 38453563 Review.
Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study).
Dowling GP, Toomey S, Bredin P, Parker I, Mulroe E, Marron J, McLoughlin O, Teiserskiene A, Power C, O'Shea AM, Greally M, Morris PG, Duke D, Hill ADK, Hennessy BT. Dowling GP, et al. Among authors: toomey s. BMC Cancer. 2024 Jan 17;24(1):91. doi: 10.1186/s12885-024-11851-4. BMC Cancer. 2024. PMID: 38233810 Free PMC article.
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer.
Cosgrove N, Eustace AJ, O'Donovan P, Madden SF, Moran B, Crown J, Moulton B, Morris PG, Grogan L, Breathnach O, Power C, Allen M, Walshe JM, Hill AD, Blümel A, O'Connor D, Das S, Milewska M, Fay J, Kay E, Toomey S, Hennessy BT, Furney SJ. Cosgrove N, et al. Among authors: toomey s. NPJ Breast Cancer. 2023 Sep 27;9(1):72. doi: 10.1038/s41523-023-00572-9. NPJ Breast Cancer. 2023. PMID: 37758711 Free PMC article.
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.
Gaynor N, Blanco A, Madden SF, Moran B, Fletcher JM, Kaukonen D, Ramírez JS, Eustace AJ, McDermott MSJ, Canonici A, Toomey S, Teiserskiene A, Hennessy BT, O'Donovan N, Crown J, Collins DM. Gaynor N, et al. Among authors: toomey s. Br J Cancer. 2023 Oct;129(6):1022-1031. doi: 10.1038/s41416-023-02375-y. Epub 2023 Jul 28. Br J Cancer. 2023. PMID: 37507543 Free PMC article. Clinical Trial.
Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).
Richards CE, Elamin YY, Carr A, Gately K, Rafee S, Cremona M, Hanrahan E, Smyth R, Ryan D, Morgan RK, Kennedy S, Hudson L, Fay J, O'Byrne K, Hennessy BT, Toomey S. Richards CE, et al. Among authors: toomey s. Int J Mol Sci. 2023 Jun 23;24(13):10545. doi: 10.3390/ijms241310545. Int J Mol Sci. 2023. PMID: 37445722 Free PMC article.
Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring.
Horgan D, Čufer T, Gatto F, Lugowska I, Verbanac D, Carvalho Â, Lal JA, Kozaric M, Toomey S, Ivanov HY, Longshore J, Malapelle U, Hasenleithner S, Hofman P, Alix-Panabières C. Horgan D, et al. Among authors: toomey s. Healthcare (Basel). 2022 Sep 7;10(9):1714. doi: 10.3390/healthcare10091714. Healthcare (Basel). 2022. PMID: 36141326 Free PMC article.
53 results